<p>Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Letter]</p>

Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study

BACKGROUND Acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) is a fatal condition without an established pharmaceutical treatment. Most patients are treated with high-dose corticosteroids and broad-spectrum antibiotics. Azithromycin is a macrolide with immunomodulatory activity and may be beneficial for treatment of acute lung injury. The objective of this study was to determine th...

Nintedanib for treating idiopathic pulmonary fibrosis

Prognostic Factors in the Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Retrospective Single-center Study

Objectives Acute exacerbation of idiopathic pulmonary fibrosis (IPF-AE) has been recognized as a fatal pulmonary disorder, but the exact prognostic factors are unknown. The aim of the present study was to analyze the clinical characteristics of patients with IPF-AE and identify the prognostic factors. Methods The medical records of 59 cases of IPF-AE were retrospectively reviewed. Clinical data...

Nintedanib: a new treatment for idiopathic pulmonary fibrosis

2015 Nintedanib is an intracellular inhibitor of tyrosine kinases that has recently been approved as a treatment for idiopathic pulmonary fibrosis (IPF) by regulatory authorities in the USA and Europe. Results from the Phase II TOMORROW trial and the two replicate Phase III INPULSIS® trials have shown that nintedanib reduces disease progression in patients with IPF by reducing the annual rate o...

Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic lung disease with no clear etiology and few therapeutic options. Growth factors that act as mediators in the development of this disease might be important therapeutic targets. Nintedanib is a triple-tyrosine kinase inhibitor and a potent antagonist of growth factors such as platelet-derived growth factor, vascular endothel...